Salsalate Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:437202892
Iupac Name:2-(2-Hydroxybenzoyl)oxybenzoic acid
Tradename:Disalcid, Salflex
Pregnancy Us:C
Legal Us:Rx-only
Cas Number:552-94-3
Atc Prefix:N02
Atc Suffix:BA06
Pubchem:5161
Drugbank:DB01399
Chebi:9014
Chemspiderid:4977
Unii:V9MO595C9I
Kegg:D00428
C:14
H:10
O:5

Salsalate is a medication that belongs to the salicylate and nonsteroidal anti-inflammatory drug (NSAID) classes.

Salsalate is the generic name of a prescription drug marketed under the brandnames Mono-Gesic, Salflex, Disalcid, and Salsitab. Other generic and brand name formulations may be available.[1]

Mechanism of action

Relative to other NSAIDs, salsalate has a weak inhibitory effect on the cyclooxygenase enzyme and decreases the production of several proinflammatory chemical signals such as interleukin-6, TNF-alpha, and C-reactive protein.

The mechanism through which salsalate is thought to reduce the production of these inflammatory chemical signals is through the inhibition of IκB kinase resulting in decreased action of NF-κB genes.[2] [3] This mechanism is thought to be responsible for salsalate's insulin-sensitizing and blood sugar lowering properties.[2]

Medical uses

Salsalate may be used for inflammatory disorders such as rheumatoid arthritis or noninflammatory disorders such as osteoarthritis.[4]

Safety

The risk of bleeding is a common concern with use of the NSAID class of medications. However, the bleeding risk associated with salsalate is lower than that associated with aspirin use.[2]

Research

Salsalate has been proposed for the prevention and treatment of type 2 diabetes mellitus due to its ability to lower insulin resistance associated with inflammation and may be useful in prediabetes.[5] However, the use of salsalate to prevent the progression from prediabetes to type 2 diabetes mellitus has received limited study.[5]

History

Salsalate had been suggested as possible treatment for diabetes as early as 1876.[5] [6] [7]

Notes and References

  1. Web site: Salsalate . drugs.com .
  2. Esser N, Paquot N, Scheen AJ . Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease . Expert Opinion on Investigational Drugs . 24 . 3 . 283–307 . March 2015 . 25345753 . 10.1517/13543784.2015.974804 . 23674166 . Review .
  3. Ridker PM, Lüscher TF . Anti-inflammatory therapies for cardiovascular disease . European Heart Journal . 35 . 27 . 1782–91 . July 2014 . 24864079 . 4155455 . 10.1093/eurheartj/ehu203 .
  4. Hardie DG . AMPK: a target for drugs and natural products with effects on both diabetes and cancer . Diabetes . 62 . 7 . 2164–72 . July 2013 . 23801715 . 3712072 . 10.2337/db13-0368 .
  5. Anderson K, Wherle L, Park M, Nelson K, Nguyen L . Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies . American Health & Drug Benefits . 7 . 4 . 231–5 . June 2014 . 25126374 . 4105730 .
  6. Powell K . Obesity: the two faces of fat . Nature . 447 . 7144 . 525–7 . May 2007 . 17538594 . 10.1038/447525a . 2007Natur.447..525P . 28974642 . free .
  7. Ebstein W . Zur therapie des diabetes mellitus, insbesondere uber die anwendung des salicylsauren natron bei demselben. Berliner Klinische Wochenschrift. 13. 337–340. 1876.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Salsalate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.